Cargando…
Early treatment-related neutropenia predicts response to palbociclib
BACKGROUND: Palbociclib is highly active in oestrogen-receptor positive (ER+) metastatic breast cancer, but neutropenia is dose limiting. The goal of this study was to determine whether early neutropenia is associated with disease response to single-agent palbociclib. METHODS: Blood count and diseas...
Autores principales: | McAndrew, Nicholas P., Dickson, Mark A., Clark, Amy S., Troxel, Andrea B., O’Hara, Mark H., Colameco, Christopher, Gallager, Maryann, Gramlich, Kristi, Zafman, Kelly, Vaughn, David, Schwartz, Gary K., O’Dwyer, Peter J., DeMichele, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492243/ https://www.ncbi.nlm.nih.gov/pubmed/32641862 http://dx.doi.org/10.1038/s41416-020-0967-7 |
Ejemplares similares
-
Neutropenia due to palbociclib: A word of caution?
por: Pramanik, Raja, et al.
Publicado: (2016) -
Neutropenia management with palbociclib in Japanese patients with advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2019) -
Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
por: Marouille, Alexandre Le, et al.
Publicado: (2021) -
Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3
por: Iwata, Hiroji, et al.
Publicado: (2021) -
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
por: Sun, James, et al.
Publicado: (2021)